Can Estrella’s EB103 challenge established CAR-T therapies in B-cell lymphoma?
Estrella has added Intermountain Health LDS Hospital as the fifth site in its Phase 1/2 STARLIGHT-1 study of EB103. Earlier testing found complete responses in five evaluable patients at the higher dose, but the small uncontrolled dataset and the company's financing position remain important development considerations.
